MARKET ANALYSIS
Gastrointestinal (GI) testing panels are used to diagnose an infection of the digestive system (GI tract) caused by various pathogens such as viruses, bacteria, and parasites in stool sample. A GI testing panel may be used in combination with other tests, such as a stool culture or an ova and parasite exam (O&P), to help establish a diagnosis because there are numerous causes of GI infections. The GI testing panel also helps in the identification of genetic components of microorganisms which further helps in preparation of effective treatment plan for speedy recovery. 

GROWTH DRIVERS AND CHALLENGES
There are various factors such as increasing prevalence of gastrointestinal infections, malignancies, and the rising demand for POC testing for gastrointestinal diseases are driving the market. According to Gastroenterological Association (AGA), in 2022, around 60-70 million Americans are suffered from gastrointestinal (GI) diseases that can also create serious disruptions to daily life, many of which can only be diagnosed by a healthcare professional. Additionally, as per statistics from the International Foundation for Gastrointestinal Disorders, Inc. published in December 2019, the prevalence of GERD is 18% - 28% in North America and 9%-26% in Europe. Therefore, it is expected that the increased prevalence of GI illnesses will support the market growth in upcoming years.

Furthermore, it is estimated that surge in product launches and the increased demand for technologically advanced molecular testing methods will support market expansion over the forecasted period. For instance, in May 2022, QIAGEN launched Higher-Capacity QIAstat-Dx Rise that can process up to 56 tests in an eight-hour shift with increased walk-away productivity and received CE-marking to run new respiratory and gastrointestinal panels. Furthermore, in October 2022, Thermo Fisher launched a new gastrointestinal bacteria detection panel, TaqPath Enteric Bacterial Select Panel. TaqPath uses polymerase chain reaction (PCR) technology to detect a range of common gastrointestinal infection bacteria in stool samples. It is validated and registered under the In Vitro Diagnostic Device Directive (IVDD) in May.

Thus, the increasing prevalence of gastrointestinal (GI) disorders motivates researchers and manufacturers to create and provide quick, accurate and innovative GI disorder detection technologies fuel the market growth. On the other hand, stringent regulation and lack of awareness about GI detection limits the gastrointestinal testing panel market growth.

REPORT SEGMENTATION AND SCOPE
The "Global Gastrointestinal Testing Panel Market Analysis to 2031" is a specialized and in-depth study focusing on the global gastrointestinal testing panel market trends and growth opportunities. The report aims to provide an overview of the global gastrointestinal testing panel market with detailed market segmentation by pathogen type, testing type, end-use, and geography. The global gastrointestinal testing panel market has witnessed high growth over the recent past and is expected to continue this trend during the forecast period. The report provides key statistics on the uses of gastrointestinal testing panels worldwide and their demand in major regions and countries. In addition, the report provides a qualitative assessment of various factors affecting the gastrointestinal testing panel market performance in major regions and countries. The report also includes a comprehensive analysis of the leading gastrointestinal testing panel market players and their key strategic developments. Several analyses on the market dynamics are also included to help identify the key driving factors, market trends, and lucrative gastrointestinal testing panel market opportunities that would, in turn, aid in identifying the major revenue pockets.

Further, ecosystem analysis and Porter's five forces analysis provide a 360-degree view of the global gastrointestinal testing panel market. This helps understand the entire supply chain and various market growth factors.

SEGMENTAL ANALYSIS
The global gastrointestinal testing panel market is segmented based on pathogen type, testing type, end-use, and geography. Based on pathogen type, the gastrointestinal testing panel market is segmented as, viruses, bacteria, and parasite. Gastrointestinal pathogen panel (GPP) tests simultaneously classify bacterial, viral, and parasitic pathogens from the stool samples of patients with suspected infectious gastroenteritis presenting in a hospital or the community. Based on testing type, the market is classified as, syndromic full, multiplex panel, and low plex panel. Multiplex panel held the largest market share in 2022 and is anticipated to expand steadily during the forecast period owing to an increase in key developments. On the basis of end-user gastrointestinal testing panel market is categorized into hospitals, diagnostic laboratories, and others.

REGIONAL ANALYSIS
The report provides a detailed overview of the global gastrointestinal testing panel market with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA) and South & Central America. North America is estimated to account for a significant gastrointestinal testing panel market share globally in 2022. The rising prevalence of gastrointestinal disorders among the population has positively contributed to the gastrointestinal testing panel market growth in North America. Europe is the second leading region expected to grow considerably with advancements in the healthcare and pharmaceutical industries. However, Asia Pacific is expected to grow significantly due to the increasing geriatric population prone to gastrointestinal disorders. Therefore, all the above-discussed factors are expected to amplify the growth of the gastrointestinal testing panel market.

INDUSTRY DEVELOPMENTS AND FUTURE OPPORTUNITIES
Partnership, acquisitions and new product launches were found to be the major strategies adopted by the players operating in the global gastrointestinal testing panel market.

In May 2022, QIAGEN N.V. launched QIAstat-Dx rise, a high-capacity version of the QIAstat-Dx automated syndromic system. It can offer diagnostic results for up to 56 tests in an eight-hour shift and 160 tests in a day utilizing eight analytical modules, and it has a random access capacity of up to 18 different tests. QIAstat-Dx Rise is a versatile new option for expanded testing capacity, building on the existing QIAstat-Dx Analyzer with up to four analytical modules.

In May 2022, Qiagen N.V. received CE Mark approval for the high-capacity syndromic testing platform, QiaStat-Dx automated syndromic testing system. Qiagen N.V. has commercially launched the QiaStat-Dx Rise platform in Europe and other territories that recognize the CE mark.

In October 2022, Thermo Fisher launched a gastrointestinal bacteria detection panel, TaqPath enteric bacterial select panel. TaqPath Panel uses polymerase chain reaction (PCR) technology to detect common gastrointestinal bacteria in stool samples.

In August 2021, QIAGEN N.V. launched the publication of a multicenter clinical study determining the accuracy of its QIAstat-Dx syndromic testing solution for detecting the causes of acute gastroenteritis. The QIAstat-Dx gastrointestinal panel delivered high performance compared to other existing multiplex tests panels in this study, which evaluated 385 patient samples at university hospital laboratories across Europe.

IMPACT OF COVID/IMPACT OF GEOPOLITICAL SCENARIO/IMPACT OF RECESSION
The covid-19 pandemic led to a decline in the progress of many industries across the globe. The shutdown of manufacturing plants and trade restrictions led to supply chain disruptions for manufacturers across the globe. The gastrointestinal testing panel market experienced a decline during the pandemic due to the limited supply and production of testing panels on global level. Conversely, the gastrointestinal testing panels market is growing after the significant efforts taken by market stakeholders and healthcare practitioners to manage the disrupted supply chain. The rising demand for gastrointestinal testing panels owing to increasing incidences of gastrointestinal complications and the rise in the geriatric population drives the market growth. Moreover, rising demand for home-based testing has created opportunities for GI testing panels during the pandemic. In 2021, the launch of vaccines controlled the infection, which led to the ease in government restrictions and the production of GI testing panels on a large scale. This further helps in stabilize the overall market growth in coming years after experiencing slightly negative effect from pandemic.

COMPETITIVE LANDSCAPE AND KEY COMPANIES
Some of the key players operating in the gastrointestinal testing panel market include, Becton, Dickinson and Company (BD), bioMérieux SA, DiaSorin S.p.A (Luminex), Quidel Corporation, QIAGEN, Seegene, Inc. Savyon Diagnostics, CerTest Biotech S.L., ARUP Laboratories and Anatolia Geneworks among others.

Access Data

Have a question?

Mrinal

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

  Speak to Analyst

Access Data